VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI), providing positive regulatory feedback on the development strategy for its lead BiTAC-TCE program. The advice supports the company’s biological rationale, safety assessments, and non-clinical development plan for its novel therapeutic platform, marking a key milestone as the company advances toward clinical studies.
The Paul-Ehrlich-Institute, Germany’s federal authority responsible for biomedicines, provided early guidance that VERAXA believes will help reduce development uncertainty by offering greater clarity before the company moves into clinical trials. Scientific Advice procedures allow drug developers to consult with regulatory experts before trials begin, helping align strategies with regulatory expectations regarding safety and tolerability.
VERAXA’s lead BiTAC-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
The announcement is significant for investors and the biotech industry because it signals that VERAXA’s proprietary BiTAC-TCE platform is on a clearer path to clinical development. Regulatory feedback from a stringent authority like PEI can de-risk the development process, potentially accelerating timelines and reducing costly missteps. For patients, this progress brings hope for novel cancer therapies that leverage the body’s immune system to target tumors more effectively.
VERAXA Biotech, an emerging leader in designing novel cancer therapies, is focused on developing next-generation antibody therapeutics. The company’s BiTAC-TCE platform represents a novel approach to engaging T-cells against cancer cells. With positive regulatory guidance in hand, VERAXA is better positioned to advance its lead candidate toward the clinic, potentially offering new treatment options for patients with limited alternatives.
The full announcement and additional details are available in the company’s newsroom at https://ibn.fm/VRXA. Further information about the regulatory feedback can be found at https://ibn.fm/zBiDU.
